Insulin Resistance in Lean PCOS

Why Standard Tests Miss It and What the Microbiome Reveals

Written by Dr. Fiona McCulloch, ND, author of 8 Steps to Reverse Your PCOS and peer reviewer of the 2023 International PCOS Guidelines.

Standard blood work (fasting glucose, HbA1c, even fasting insulin) can come back completely normal in lean PCOS patients, yet insulin resistance may still be driving symptoms. This is one of the most common problems we see in the clinic. Even when fasting insulin levels are normal, post-meal insulin can be very high, sometimes double the normal amount. Approximately 50% of lean PCOS patients whose fasting numbers look normal will show hyperinsulinemia when tested with the insulin assay with glucose tolerance test. At White Lotus Clinic in Toronto, comprehensive metabolic assessment is a core part of how we evaluate PCOS, including in patients who have been told their metabolism is fine.

If you have PCOS and have been told your metabolism is fine despite persistent symptoms, a comprehensive metabolic assessment can help clarify the picture.

When Standard Blood Work Says You're Fine, But You're Not

Lean PCOS patients who come to the clinic with concerns about insulin resistance tend to fall into two groups. The first group has been told they have insulin resistance and told to lose weight. They try to do that, and nothing changes with their PCOS. This is a very common problem that we see. The second group has insulin resistance that simply is not being checked properly. Their blood sugar levels are completely normal, yet their insulin levels are very high. In these patients, nothing is found on standard testing, but they always feel like something is wrong with their blood sugar because they do respond to diet and they do gain weight around their midsection even though they are lean.

The symptoms lean PCOS patients experience despite normal blood work are consistent and recognizable: sensitivity to dietary changes, visceral fat distribution around the midsection despite a lean frame overall, energy crashes, sugar cravings, fatigue, and brain fog. Many also have skin signs of insulin resistance (acanthosis nigricans or skin tags) that no one has connected to their metabolic picture. Gut symptoms are also common regardless of whether insulin resistance is mild or severe: abnormal appetite, cravings, changes in satiety and fullness, bloating, and gut discomfort. These gastrointestinal symptoms are related to hormones like GLP-1 that play out in lean PCOS and are frequently overlooked.

Patients report going through sometimes a decade of trying to get the proper testing and it is not done. This is not a failure of their previous care: standard metabolic tests like fasting glucose and HbA1c are designed to detect diabetes, which is a later stage of metabolic dysfunction. For lean PCOS patients, these tests often appear normal because the pancreas is still compensating. The assumption that normal weight means normal metabolism is one of the most persistent barriers to proper assessment. Understanding the different presentations of PCOS, and how insulin resistance can be present in any of them, is essential for identifying what has been missed.

Detecting What Standard Tests Miss

Standard metabolic screening (fasting glucose, HbA1c, even fasting insulin) is designed to detect diabetes or advanced insulin resistance. For lean PCOS patients, these tests often come back normal because the metabolic dysfunction exists at a stage that standard screening was not designed to detect. The insulin assay with glucose tolerance test measures insulin at multiple points during a glucose challenge, capturing the full insulin response curve: the timing, magnitude, and duration of the body’s insulin response. This is the test that reveals the hidden hyperinsulinemia that fasting tests miss. Approximately 50% of lean PCOS patients whose fasting numbers are normal will show an abnormal insulin pattern on this test.

The three most common abnormal patterns we see in lean PCOS patients on the insulin assay with glucose tolerance test are:

A normal fasting insulin followed by a very high spike, sometimes double the normal amount
Insulin levels that stay high for too long and do not come back down by the end of the test
Insulin that spikes, goes back down, and then rises again

All three patterns are invisible on a single fasting test. They require a multi-point insulin measurement during a glucose challenge to detect.

Dr. Fiona McCulloch, ND, FABNE, has a clinical focus in PCOS metabolic assessment with approximately 25 years of clinical experience. She is the author of 8 Steps to Reverse Your PCOS, which covers insulin resistance as a core PCOS driver including in lean presentations. She served as a peer reviewer for the 2023 International PCOS Guidelines and holds a fellowship from the American Board of Naturopathic Endocrinology (FABNE) in functional endocrinology, directly relevant to metabolic assessment and insulin dynamics. White Lotus Clinic offers comprehensive metabolic testing including the insulin assay with glucose tolerance test, lipid panels, liver enzymes, hormonal panels, and GI MAP stool testing.

Why Fasting Glucose and Standard Blood Work Miss Insulin Resistance in Lean PCOS

Each standard metabolic test was designed for a purpose, but the insulin resistance that lean PCOS patients experience often exists in the gap between what these tests detect and what is actually happening metabolically. Fasting glucose detects diabetes, a late stage of metabolic dysfunction when blood sugar regulation has already broken down. HbA1c reflects a three-month average of blood sugar, useful for diabetes monitoring, but insensitive to the postprandial insulin spikes that characterize lean PCOS. Fasting insulin is a step closer, but it captures only a single snapshot at rest. For lean PCOS patients, the pancreas may be compensating effectively in a fasted state; it is only when challenged with glucose that the dysfunction becomes visible.

The insulin assay with glucose tolerance test captures what these tests miss: the full insulin response curve under glucose challenge. It reveals how high insulin spikes, how long it stays elevated, and whether it returns to baseline normally. For lean PCOS patients whose fasting labs have always looked normal, this test often tells a different story. All of the abnormal patterns we describe (the high spikes, the prolonged elevation, the biphasic rise) are situations that we commonly see in this particular presentation of PCOS with insulin resistance. The test provides clinical validation for what the patient has felt was true: something is going on with her metabolism. Read the comprehensive guide to the insulin assay with glucose tolerance test.

Insulin resistance can also be suggested by other markers: lipid panels, liver enzymes, weight distribution, particularly midsection weight gain despite being lean overall, and physical symptoms including skin signs like acanthosis nigricans. Fasting insulin can only show you something: the full picture requires looking at multiple markers together.

The Gut Microbiome and Insulin Resistance in PCOS

Research has identified distinct gut microbiome signatures in PCOS patients, including reduced bacterial diversity and decreased populations of short-chain fatty acid (SCFA)-producing bacteria. SCFAs play a role in insulin sensitivity through multiple pathways: they support intestinal barrier function, stimulate GLP-1 secretion from enteroendocrine cells, and modulate systemic inflammation. Studies have shown that lean PCOS patients can have altered microbiome profiles associated with insulin resistance markers that are not detectable on standard metabolic screening, suggesting that the gut microbiome may be a mediating factor in the hidden hyperinsulinemia that characterizes this presentation.

In clinical practice, the gut-metabolism-hormone connection plays out clearly in lean PCOS patients. Patients commonly experience abnormal appetite, cravings, changes in satiety and fullness, bloating, and gut discomfort, regardless of whether their insulin resistance is mild or severe. For many patients, these gastrointestinal symptoms have never been connected to their PCOS or their metabolic picture. The microbiome framework provides a unifying explanation: gut dysbiosis can affect insulin signaling, appetite regulation through gut peptides like GLP-1, and hormonal balance simultaneously.

Berberine and metformin, both commonly used in insulin resistance management, share a mechanism of action that works partly through the gut microbiome: increasing populations of beneficial SCFA-producing bacteria, improving intestinal barrier function, and modulating bile acid metabolism. This means addressing the microbiome is not separate from addressing insulin resistance; the two are connected mechanistically. How berberine and metformin work through the gut microbiome provides additional detail on this shared mechanism. GI MAP stool testing can help evaluate the gut microbiome as part of a comprehensive metabolic assessment.

Insulin Resistance in Lean PCOS and the Menopause Transition

Estrogen has direct insulin-sensitizing effects. During reproductive years, this provides a metabolic buffer, particularly for lean PCOS patients whose hyperinsulinemia may be compensated and invisible on standard tests. As estrogen declines during perimenopause, this protective buffer diminishes. With lean patients approaching perimenopause, what we typically see is a worsening of this insulin resistance because without the effects of estrogen, there is generally a worsening of the metabolism. The compensated hyperinsulinemia that was manageable during reproductive years may become more clinically significant as this estrogen buffer decreases.

The trajectory for lean PCOS patients approaching perimenopause is similar to classic PCOS, just not as severe. The management approach is similar: strength training, dietary changes, supporting liver and thyroid function. The main difference entering perimenopause is the addition of hormone replacement therapy when needed or warranted, because HRT can be beneficial for any PCOS patient in perimenopause, regardless of whether their presentation is lean or classic. The real difference is between reproductive age and perimenopause age, not between lean and classic.

The gut microbiome also plays a role in estrogen metabolism through the estrobolome: the collection of bacteria that regulate estrogen recirculation. During perimenopause, as ovarian estrogen production declines, the estrobolome’s role in estrogen metabolism becomes proportionally more significant. For lean PCOS patients with existing gut dysbiosis, the metabolic transition through perimenopause may be compounded by changes in estrogen metabolism via the gut. Learn more about the estrobolome and estrogen metabolism, PCOS and perimenopause, and the menopause and perimenopause program at White Lotus Clinic.

Addressing Insulin Resistance in Lean PCOS

Management of insulin resistance in lean PCOS addresses the modifiable factors that contribute to metabolic dysfunction. This commonly includes dietary changes focused on macronutrient balance, exercise with an emphasis on strength training, berberine for insulin sensitization, which works partly through a microbiome-mediated mechanism, and assessment of contributing factors including liver function, thyroid function, and gut health. For lean PCOS patients, the insulin resistance level is usually not as intense as in classic PCOS. We are often looking at a difference in duration; it may not take as long to address. The treatments are similar, but the clinical trajectory is typically shorter.

The dietary approach for lean PCOS is not caloric restriction or weight loss; that is irrelevant and frustrating for patients who are not overweight. The goal is macronutrient balance, fiber diversity, and blood sugar stability, supporting the microbiome and insulin signaling simultaneously. The food insulin demand approach provides a framework for understanding how different foods affect the insulin response, which is directly relevant for lean PCOS patients managing their metabolic picture through diet.

When patients learn that their insulin resistance has been present but missed, sometimes for years, the clinical reframe is important. We finally found the reason for what is happening here. This is good news. We now know what to focus on because actually treating it is very logical. We have a lot of ways that work to help with this issue. Once you know exactly the factors involved, whether it is insulin dynamics, microbiome status, liver or thyroid function, successful treatment is very possible. Learn more about evidence-based supplements for insulin resistance.